Pre-made Lirentelimab benchmark antibody ( Whole mAb, anti-SIGLEC8/Siglec-8 therapeutic antibody, Anti-SAF2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-315
Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lirentelimab (sold under the brand name AK002) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis. Adverse reactions include infusion reactions, which are mild to moderate and typically occur following the first infusion.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Lirentelimab biosimilar, Whole mAb, Anti-SIGLEC8/Siglec-8 Antibody: Anti-SAF2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease|
|Conditions Discontinued||Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis|